Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVZO-103 in locally advanced or metastatic urothelial cancer or other solid tumors
NCT07193511Phase 2Recruiting
- Sponsor
- Avenzo Therapeutics
- Start
- Oct 2025
- Primary completion
- Mar 2030
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of AVZO-103 in urothelial carcinoma (UC), solid tumor, sponsored by Avenzo Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
AVZO-103
03
Conditions
urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT07193511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193511.